



MICROBA™

Precision Microbiome Science

November 2021 | Private and confidential

Disclaimer

This presentation (**Presentation**) has been prepared by Microba Life Sciences Limited (**Microba**). By accepting a copy of this Presentation, the recipient acknowledges and agrees that this Presentation and all of the information contained in it is confidential and must be kept strictly confidential. By accepting this Presentation, you represent and warrant that you are entitled to receive this Presentation in accordance with the restrictions, and agree to be bound by the limitations, contained within it.

Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of this Presentation, being 10 November 2021. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.

Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs. This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.

Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Financial data – All dollar values in Australian dollars (A\$ or \$) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. The historical financial information for the 12 months ended FY2019, FY2020 and FY 2021 have been prepared based on audited financial information. The pro-forma financial information, while based on audited financial information for FY2021 has not been reviewed. The historical financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba's views on its future financial condition and/or performance.

Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation.

Presenter

Dr Luke Reid
Chief Executive Officer



Investment Highlights

- 1 Microba has **world leading technology in the emerging US\$4.89 billion microbiome sector¹**. This sector is transforming the large chronic disease management market².
- 2 **Building the leading global microbiome testing company.** 20k test reports sold to date with a strong growth profile
- 3 **Partnerships established with market leaders** incl. SYNLAB (GR:SYAB), Illumina (NASDAQ: ILMN), and Unilever (LON: ULVR)
- 4 **Large, unique, proprietary microbiome databank** driving multiple therapeutic opportunities through a capital light and repeatable platform
- 5 Lead drug candidate for **Inflammatory Bowel Disease entering Phase Ib trial in 2022**
- 6 **Cancer program initiated with leading cancer institutes** across US and AU incl. Moffitt, Mayo, MD Anderson and others
- 7 Globally leading microbiome expertise complimented by drug discovery experts including Prof. Ian Frazer and deep commercialization capability.

Executive Summary

<p>Overview</p>	<ul style="list-style-type: none"> Company formed in 2017 to acquire co-founder developed IP from the University of Queensland 20,000+ microbiome test reports sold to date Global partnerships established with multinational companies Team includes global experts in drug discovery and technology commercialisation Large proprietary databank drives the discovery of multiple therapeutic assets Lead drug candidate for Inflammatory Bowel Disease entering Phase Ib trial in 2022 Headquartered in Brisbane, Australia. Now 55 FTEs including 25 PhDs based across AUS and USA 							
<p>Commercial Model</p>	<p style="text-align: center;">Market</p> <p style="text-align: center;">Microba with it's world leading technology operates in the emerging US\$4.89 billion microbiome sector¹ which is transforming the large chronic disease management market²</p> <table border="1" style="width: 100%;"> <tr> <td data-bbox="435 730 1429 1286"> <p style="text-align: center;">SERVICES</p> <p style="text-align: center;">Global microbiome testing services powered by Microba's world-leading gut microbiome Analysis Platform</p> <table border="1" style="width: 100%;"> <tr> <td data-bbox="435 887 919 1286"> <p>Distribution Model</p> <ul style="list-style-type: none"> Partner distribution model scales global access to the company's Analysis Platform Enables partners to quickly launch a microbiome test powered by Microba's technology </td> <td data-bbox="919 887 1429 1286"> <p>Distribution Partners</p> <p>Existing partners include:</p> <ul style="list-style-type: none"> Synlab (EU) Macrogen (US) Metagenics (AU & NZ) </td> </tr> </table> </td> <td data-bbox="1429 730 2491 1286"> <p style="text-align: center;">THERAPEUTICS</p> <p style="text-align: center;">Developing novel monoclonal microbial cell therapies through Microba's data-driven Therapeutics Platform</p> <table border="1" style="width: 100%;"> <tr> <td data-bbox="1429 887 1888 1286"> <p>Inflammatory Bowel Disease</p> <ul style="list-style-type: none"> Potent novel monoclonal microbial drug candidates developed Manufacturing initiated Lead candidate entering Phase Ib trial in 2022 </td> <td data-bbox="1888 887 2491 1286"> <p>Cancer Immunotherapy</p> <ul style="list-style-type: none"> Discovery program initiated Large study across US and AU together with leading cancer centres including Moffitt, Mayo Clinic, MD Anderson and others </td> </tr> </table> </td> </tr> </table>		<p style="text-align: center;">SERVICES</p> <p style="text-align: center;">Global microbiome testing services powered by Microba's world-leading gut microbiome Analysis Platform</p> <table border="1" style="width: 100%;"> <tr> <td data-bbox="435 887 919 1286"> <p>Distribution Model</p> <ul style="list-style-type: none"> Partner distribution model scales global access to the company's Analysis Platform Enables partners to quickly launch a microbiome test powered by Microba's technology </td> <td data-bbox="919 887 1429 1286"> <p>Distribution Partners</p> <p>Existing partners include:</p> <ul style="list-style-type: none"> Synlab (EU) Macrogen (US) Metagenics (AU & NZ) </td> </tr> </table>	<p>Distribution Model</p> <ul style="list-style-type: none"> Partner distribution model scales global access to the company's Analysis Platform Enables partners to quickly launch a microbiome test powered by Microba's technology 	<p>Distribution Partners</p> <p>Existing partners include:</p> <ul style="list-style-type: none"> Synlab (EU) Macrogen (US) Metagenics (AU & NZ) 	<p style="text-align: center;">THERAPEUTICS</p> <p style="text-align: center;">Developing novel monoclonal microbial cell therapies through Microba's data-driven Therapeutics Platform</p> <table border="1" style="width: 100%;"> <tr> <td data-bbox="1429 887 1888 1286"> <p>Inflammatory Bowel Disease</p> <ul style="list-style-type: none"> Potent novel monoclonal microbial drug candidates developed Manufacturing initiated Lead candidate entering Phase Ib trial in 2022 </td> <td data-bbox="1888 887 2491 1286"> <p>Cancer Immunotherapy</p> <ul style="list-style-type: none"> Discovery program initiated Large study across US and AU together with leading cancer centres including Moffitt, Mayo Clinic, MD Anderson and others </td> </tr> </table>	<p>Inflammatory Bowel Disease</p> <ul style="list-style-type: none"> Potent novel monoclonal microbial drug candidates developed Manufacturing initiated Lead candidate entering Phase Ib trial in 2022 	<p>Cancer Immunotherapy</p> <ul style="list-style-type: none"> Discovery program initiated Large study across US and AU together with leading cancer centres including Moffitt, Mayo Clinic, MD Anderson and others
<p style="text-align: center;">SERVICES</p> <p style="text-align: center;">Global microbiome testing services powered by Microba's world-leading gut microbiome Analysis Platform</p> <table border="1" style="width: 100%;"> <tr> <td data-bbox="435 887 919 1286"> <p>Distribution Model</p> <ul style="list-style-type: none"> Partner distribution model scales global access to the company's Analysis Platform Enables partners to quickly launch a microbiome test powered by Microba's technology </td> <td data-bbox="919 887 1429 1286"> <p>Distribution Partners</p> <p>Existing partners include:</p> <ul style="list-style-type: none"> Synlab (EU) Macrogen (US) Metagenics (AU & NZ) </td> </tr> </table>	<p>Distribution Model</p> <ul style="list-style-type: none"> Partner distribution model scales global access to the company's Analysis Platform Enables partners to quickly launch a microbiome test powered by Microba's technology 	<p>Distribution Partners</p> <p>Existing partners include:</p> <ul style="list-style-type: none"> Synlab (EU) Macrogen (US) Metagenics (AU & NZ) 	<p style="text-align: center;">THERAPEUTICS</p> <p style="text-align: center;">Developing novel monoclonal microbial cell therapies through Microba's data-driven Therapeutics Platform</p> <table border="1" style="width: 100%;"> <tr> <td data-bbox="1429 887 1888 1286"> <p>Inflammatory Bowel Disease</p> <ul style="list-style-type: none"> Potent novel monoclonal microbial drug candidates developed Manufacturing initiated Lead candidate entering Phase Ib trial in 2022 </td> <td data-bbox="1888 887 2491 1286"> <p>Cancer Immunotherapy</p> <ul style="list-style-type: none"> Discovery program initiated Large study across US and AU together with leading cancer centres including Moffitt, Mayo Clinic, MD Anderson and others </td> </tr> </table>	<p>Inflammatory Bowel Disease</p> <ul style="list-style-type: none"> Potent novel monoclonal microbial drug candidates developed Manufacturing initiated Lead candidate entering Phase Ib trial in 2022 	<p>Cancer Immunotherapy</p> <ul style="list-style-type: none"> Discovery program initiated Large study across US and AU together with leading cancer centres including Moffitt, Mayo Clinic, MD Anderson and others 			
<p>Distribution Model</p> <ul style="list-style-type: none"> Partner distribution model scales global access to the company's Analysis Platform Enables partners to quickly launch a microbiome test powered by Microba's technology 	<p>Distribution Partners</p> <p>Existing partners include:</p> <ul style="list-style-type: none"> Synlab (EU) Macrogen (US) Metagenics (AU & NZ) 							
<p>Inflammatory Bowel Disease</p> <ul style="list-style-type: none"> Potent novel monoclonal microbial drug candidates developed Manufacturing initiated Lead candidate entering Phase Ib trial in 2022 	<p>Cancer Immunotherapy</p> <ul style="list-style-type: none"> Discovery program initiated Large study across US and AU together with leading cancer centres including Moffitt, Mayo Clinic, MD Anderson and others 							
<p>Technology</p>	<p style="text-align: center;">Analysis Platform</p> <p style="text-align: center;">Gut microbiome analysis technology which measures the gut microbiome with world-leading coverage and precision</p>	<p style="text-align: center;">Discovery Platform</p> <p style="text-align: center;">Proprietary microbiome databank comprising >1.2M microbial genomes driving the discovery of therapeutic leads</p>	<p style="text-align: center;">Therapeutic Platform</p> <p style="text-align: center;">Data-driven therapeutics platform enabling rapid development of novel monoclonal microbial cell therapies</p>					

Microba Board and Senior Management

World class team with diverse skills across science, medicine and technology commercialisation



Dr Luke Reid
Chief Executive Officer

Experienced biotech executive; ex-UniQuest one of the global leaders in commercialisation of university technology

Dr Luke Reid is an experienced research and technology commercialisation executive. Previous roles include working with UniQuest, Dupont Pioneer and Novozymes.



Pasquale Rombola
Chairman

Experienced executive; ex-Morgan Stanley and Deutsche Bank

Mr Rombola has over 30 years of corporate and financial experience in Australia, Asia and the United Kingdom. Current Non-Executive Director of Audeara Limited (ASX: AUA), and former Chairman and Director of Helix Resources Limited (ASX:HLX).



Prof. Ian Frazer
Deputy Chairman and
Chair Medical Advisory Board

Chair Australian Medical Research Advisory Board; Australian of the Year 2006

Professor Frazer is a clinical immunologist and inventor of the Gardasil vaccine, Professor at the University of Queensland and an advisory board member of several other companies and non-profit organisations.



Prof Gene Tyson
Co-Founder,
Non-Executive Director

Professor of Microbial Genomics at The Queensland University of Technology

Professor Tyson is considered a world-leading expert in microbial analysis with previous tenure at UC Berkeley, MIT and UQ. He published the first paper to use metagenomics for profiling microbial communities.



Prof. Phil Hugenholtz
Co-Founder, Chair of
Scientific Advisory Board

Director of the Australian Centre for Ecogenomics; former Director of the Microbial Ecology and Metagenomic Programs at the Joint Genome Institute (JGI)

Professor Hugenholtz has made landmark contributions to the understanding of uncultured microbial diversity, and led the development of new tools and standards in the field.



Assoc. Prof. Lutz Krause
Chief Scientific Officer



Dr Caroline Popper
Non-Executive
Director



Dr Jakob Begun
Medical Advisory Board,
Chair - IBD Advisory Panel




Dr Nicola Angel
Laboratory Director



John Cullity
Commercial Advisor



Holly Bauzon
Vice President, Commercial
Development



Mark Parker
Global Business
Development

Opportunity Overview

Resolving chronic disease with
Precision Microbiome Science

**World leading
microbiome analysis
technology** unlocks
routine testing and
microbiome therapies

up to **95%**
coverage¹

up to **34x**
more accurate²

Other
Technology

Microba
Technology



THE UNIVERSITY
OF QUEENSLAND
AUSTRALIA

Published in
 **frontiers**
in Microbiology

MICROBA

¹ Calculated by analysing more than 10k samples across Microba's databank
² Microba achieves 6-34x fewer false positive results than academic competitors
Parks, Donovan H., et al. "Evaluation of the Microba Community Profiler for Taxonomic Profiling of Metagenomic Datasets From the Human Gut Microbiome." *Frontiers in microbiology* 12 (2021).

*Illustrative visualisation of the gastrointestinal tract and the additional
bacteria visible to Microba with its platform technology*

This graphic is for illustrative purposes only

The gut microbiome plays a key role in health & disease

Modifying the gut microbiome; a key missing piece to resolving chronic disease

6 in 10


People have a chronic disease¹

>100

Clinical studies demonstrating that **microbiome modulation can change chronic disease outcomes**²

What is the gut microbiome?

The community of microorganisms that inhabit the lower digestive tract containing trillions of microbial cells known as the gut microbiome.




Microbiome science is changing medicine and will **transform chronic disease management**



Microbiome therapy to treat chronic diseases

Microbiome modulating primary and adjuvant therapies are currently being developed to address autoimmune, inflammatory, metabolic, mental health disorders and cancer immunotherapy




Microbiome testing to match patients with the right treatment

Microbiome biomarkers and signatures are being developed for diagnosis, screening, drug response assessment and health risk monitoring.

Microba with its world leading technology operates in the **emerging US \$4.89 billion microbiome sector¹** which is transforming the large chronic disease management market²

Microba's Commercial Model

Global testing services build a proprietary databank driving transformative novel therapies




Microbiome Services

Driving global revenues
and data growth


Services Overview

- Powered by Microba's leading microbiome Analysis Platform.
- **Distribution partners in US, EU & AU** offer a microbiome test to their existing customer base with Microba technology.
- Key **distribution partners established** including Synlab (EU), Macrogen (US), Metagenics (AU & NZ)
- **Microba's services are trusted by large multinationals** including Unilever, Illumina and other top pharma and nutrition companies
- Global services revenue expected to accelerate post COVID and with new distribution partners.




Partner distribution model


Scalable global testing services



Microbiome services drive **revenue and data growth**



Global services revenue expected to accelerate post COVID and with new distribution partners.



Data from services build proprietary databank powering therapeutic discovery

Global distribution partners

Distribution agreements executed with global market leaders to distribute microbiome testing solutions powered by Microba's world leading Analysis Platform technology.

 <p>Metagenics</p> <p>AU & NZ</p> <ul style="list-style-type: none"> • Metagenics is a leader in functional nutrition • Large allied health clinician customer base • In 2019, the Company finalised a distribution partnership for AU & NZ 	 <p>Humanizing Genomics macrogen</p> <p>US</p> <ul style="list-style-type: none"> • Macrogen is a leading company in precision medicine and biotechnology • Psomagen is Macrogen's US associated entity • In 2019 the Company signed a distribution partnership for the US 	 <p>SYNLAB</p> <p>Europe</p> <ul style="list-style-type: none"> • Europe's largest pathology company • Presence in over 40 countries • Manage 500m tests a year for 10m patients • Expansion initiated into 7 additional countries in 2021 	 <p>TO BE ANNOUNCED</p> <p>Middle East</p> <ul style="list-style-type: none"> • Leading health-tech company • Harnessing data and advanced technologies to unlock personalised and preventive care • MOU signed to target consumer & healthcare market 	 <p>TO BE ANNOUNCED</p> <p>US</p> <ul style="list-style-type: none"> • Leading GI pathology company • >10,000 purchasing clinicians • MOU signed to target US healthcare market 	 <p>TO BE ANNOUNCED</p> <p>AU</p> <ul style="list-style-type: none"> • Fast growth innovative consumer healthcare company • MOU signed to target AU consumer market
<p>Launched Mid 2019</p>	<p>Launched Late 2019</p>	<p>Launched Mid 2021</p>	<p>Planned Launch Early 2022</p>	<p>Planned Launch Mid 2022</p>	<p>Planned Launch Mid 2022</p>

Large multinationals trust Microba for microbiome analysis services

Multinational Pharmaceutical and Consumer Health companies come to Microba for research services to access the company's leading technology and databank.



illumina®

Undisclosed
Global Nutrition
Company

Undisclosed
Global Pharmaceutical
Company

Microba's technology and databank enables precision research.

Client research projects include: revealing new connections between the microbiome, health and disease; drug-microbiome interactions to assist pharmaceutical companies to develop safe and effective drugs; and consumer health product discovery.

Microbiome Databank

Driving therapeutic discovery

Large, unique, proprietary databank

driving multiple therapeutic opportunities

Proprietary Databank


11K samples
1.2M genomes
11.7M genes

 Health Data

 Biome Data



Revealing disease signatures



 Disease  Health



Already producing novel therapeutic leads across 18 diseases



Microbiome Therapeutics


Developing novel monoclonal
microbial cell therapies

Therapeutics Overview

- Strategy is to leverage our proprietary databank to develop multiple therapeutic opportunities and partner with large pharma companies
- **Human first, data-driven** approach to drug discovery is highly sought after by pharmaceutical companies.
- Flagship program is in Inflammatory Bowel Disease (IBD) which **affects 6.8m people globally**¹.
- Program has progressed well with preclinical data showing excellent results in animal models of disease.
- Cancer program initiated with leading cancer institutes across US and AU
- Excellent deal precedents - Gilead entered into \$1.5bn partnership with Second Genome².







Repeatable, scalable, data-driven platform **discovering novel monoclonal microbial cell therapies**



Proprietary microbiome databank driving **multiple therapeutic opportunities through a capital light platform**

Inflammatory Bowel Disease program delivering **potent orally delivered monoclonal microbial cell therapy**



- MH23 stimulates epithelial restitution and mucosal healing, a **key gap in existing therapy**
- Lead candidate in **manufacturing for a Phase 1b** trial in patients with mild to moderate Ulcerative Colitis

2020 sales of leading immuno-modulatory drugs used to treat IBD:

HUMIRA \$20.4B¹ | REMICADE \$4.2B²

Repeatable human first, data-driven therapeutic platform

Demonstrating rapid translation from data to first in human

CANDIDATE SELECTION PROCESS

4,784 Bacteria observed
in Microba dataset

Many bacteria differentially
abundant in health vs IBD

25 bacteria
prioritised based
on signal strength

8-10 isolated using genome
directed isolation
technique

In vitro & *in vivo* testing
completed on 8-10 leads

3 Lead candidates
selected based on efficacy
& safety profile

Lead candidate selected &
manufactured under GMP
for Phase Ib clinical trial

18 months

Microba
Today
Is significantly
progressed


Inflammatory
Bowel Disease
Program

Cancer program

Developing a microbiome-derived cancer immunotherapy

Developing breakthrough microbiome-derived cancer immunotherapy together with leading Cancer Centers across US and AU.

Development partners



- Between **42% - 70%** of patients do not **respond** to ICI therapy^{1,2}
- Modulation of the gut microbiome using **fecal microbiome transplant improved ICI response** in Phase I and II studies^{3,4}
- **Over 30 published studies** support the influence of the gut microbiome on ICI response
- Targeting the discovery and development of an **effective microbiome-derived adjuvant therapy to increase ICI response rate**

Therapeutic pipeline

Repeatable, capital light therapeutic platform

Inflammatory Bowel Disease

- USD 19.2B market size with 4.8% CAGR¹
- Microba candidates addressing key gap in current therapy
- Strong deal precedents

Development partners



Cancer immunotherapy

- Between 42% - 70% of patients do not respond to ICI therapy^{2,3}
- Market is expected to be worth >50B by 2025
- Opportunity to develop a microbiome adjuvant therapy to improve ICI response

Development partners



Additional program opportunities

Inflammatory & autoimmune

- Allergy
- Rheumatoid Arthritis

Cardiometabolic

- Diabetes
- Non-alcoholic fatty liver disease

Mental health conditions

- Anxiety & Depression
- Alzheimer's


Growth sector with **big pharma engaged**



\$1.5B USD transaction



Agreement to identify biomarkers associated with Gilead compounds for multiple diseases, and to identify new targets and drug candidates inflammatory bowel disease.¹



\$534M USD transaction



Agreement to discover biomarker signatures of drug response, new live bacterial therapeutics and novel targets for inflammatory bowel disease.²



\$1.9B USD transaction



Agreement to commercialise Seres novel therapeutic assets in the fields of Clostridium difficile infections and Inflammatory Bowel Disease.³

¹ <https://microbiomepost.com/gilead-signs-potential-1-5-billion-deal-with-second-genome/>

² <https://www.fiercebiotech.com/biotech/genentech-signs-534m-deal-microbiotica-search-gut-bacteria-for-ibd-targets-new-drugs>

³ <https://www.reuters.com/article/us-nestle-seres-deals-idUSKCN0UP1VP20160111>

Summary

- **Building the leading microbiome testing company**
Globally scalable distribution partner model with strong growth prospects post COVID
- **Large, unique, proprietary databank**
Driving multiple therapeutic opportunities
- **Repeatable, scalable drug development platform**
Generating high-value, potent drug candidates with strong deal precedents
- **Microbiome segment rapidly growing and attracting multinational investment**
Strong technology platform positions Microba for a dominant market position

Contact



Dr Luke Reid

Chief Executive Officer
luke.reid@microba.com



Pasquale Rombola

Chairman
pasquale.rombola@microba.com

Head Office

Level 10, 324 Queen Street,
Brisbane, QLD Australia

Laboratory

Princess Alexandra Hospital,
Brisbane, QLD Australia

Appendix

Board of Directors



Pasquale Rombola
Chairman
Non-Executive Director

Mr Rombola has over 30 years of corporate and financial experience in Australia, Asia and the United Kingdom. He spent 19 years in senior positions with Morgan Stanley and Deutsche Bank, including 7 years in the role of Managing Director. Mr Rombola is a current Non-Executive Director of Audeara Limited, a leading hearing health company (ASX: AUA), he is the Chairman of Advantage Agriculture Pty Ltd a private agribusiness company. He was also formerly the Chairman and Director of Helix Resources Limited (HLX). Mr Rombola holds a Bachelor of Economics from the University of Western Australia.



Prof. Ian Frazer
Deputy Chairman and
Chair Medical Advisory Board

Professor Frazer is a clinician scientist, trained as a clinical immunologist. He is a Professor at the University of Queensland and is the current Chairman of the Australian Medical Research Advisory Board (AMRAB) which advises the Minister for Health on prioritising spending from the Medical Research Future Fund (MRFF). He is recognised as co-inventor of the technology enabling Gardasil - the leading vaccine currently used worldwide to help prevent cervical cancer.

Professor Frazer holds a Doctor of Medicine from the University of Melbourne and the following degrees from the University of Edinburgh: Bachelor of Medicine, Bachelor of Surgery and Bachelor of Science (Hons).



Dr Caroline Popper
Non-Executive
Director

Dr Popper is a US-based pathologist and business consultant with more than 20 years' experience in the international diagnostics, medical devices and drug discovery fields, including 10 years in senior management and marketing roles at the leading medical technology firm, Becton Dickson & Company. Dr Popper has served in senior managerial and advisory positions at a variety of Fortune 500 and start-up companies, including bioMerieux and MDS Proteomics.

She holds a Bachelor of Medicine from the University of the Witwatersrand, Johannesburg; Master of Public Health – Health Policy and Health Economics from Johns Hopkins University, Baltimore.



Prof Gene Tyson
Co-Founder,
Non-Executive Director

Professor Tyson is a Professor of Microbial Genomics at The Queensland University of Technology and is the Director of the Centre for Microbiome Research.

Whilst at the University of California, Berkeley he was involved in publishing the first paper regarding the use of metagenomic sequencing for assessing microbial communities. Professor Tyson is also considered a world-leading expert in microbial analysis.

Professor Tyson holds a Bachelor Science (Hons) from the University of Queensland and a PhD from the University of California, Berkeley.



Dr Hyungtae Kim
Non-Executive Director

Dr Hyungtae Kim is an internationally experienced leader in the genomics field having held the positions of Chief Executive Officer of MacroGen Inc (MacroGen) from 2008 to 2014 and Chief Executive Officer, MacroGen Europe from 2015 to 2017.

Dr Kim is a Director of MacroGen Inc, a company listed on the KOSDAQ in South Korea.

Dr Kim is also a Director of the Gongwu Genome Information Foundation.

Dr Kim holds a PhD in molecular biology from George Washington University in Washington DC, USA.



Richard Bund
Non-Executive Director

Mr Bund is a Chartered Accountant and Director of Equipe Advisory Accounting firm. Mr Bund has more than 20 years experience in accounting and corporate finance and is the director of several private Australian companies.

Mr Bund is a Member of Chartered Accountants Australia and New Zealand and the Taxation Institute of Australia. He holds a Bachelor of Commerce (Accounting) from the University of Adelaide and a Graduate Diploma in Chartered Accounting from Chartered Accountants Australia and New Zealand.

Medical Advisory Board



Prof. Ian Frazer

Deputy Chairman and Chair Medical Advisory Board, Clinical Immunologist

Professor Frazer is a clinician scientist, trained as a clinical immunologist. He is a Professor at the University of Queensland and is the current Chairman of the Australian Medical Research Advisory Board (AMRAB) which advises the Minister for Health on prioritising spending from the Medical Research Future Fund (MRFF). He is recognised as co-inventor of the technology enabling Gardasil - the leading vaccine currently used worldwide to help prevent cervical cancer.

Professor Frazer holds a Doctor of Medicine from the University of Melbourne and the following degrees from the University of Edinburgh: Bachelor of Medicine, Bachelor of Surgery and Bachelor of Science (Hons).



Dr Jakob Begun

Medical Advisory Board, Chair IBD Advisory Panel, Gastroenterologist

Dr Jakob Begun is a Practising Clinical Gastroenterologist and Senior Research Fellow in the Immunity, Infection, and Inflammation Program at Mater Research, The University of Queensland.

He established an IBD centre at Queen Elizabeth II Hospital and an adolescent and young adult IBD centre at the Mater Hospital in Brisbane. Dr Begun is a senior lecturer at The University of Queensland School of Medicine and has a basic and translational laboratory at the Translational Research Institute. He maintains active collaborations with researchers at Harvard University and has formed new collaborations with researchers across Australia through his role as Chair of the Australia and New Zealand IBD Consortium.



Dr Paul Griffin

Medical Advisory Board, Infectious Disease Physician

Dr Paul Griffin is an Infectious Diseases Physician and microbiologist and was appointed as the Director of Infectious Diseases at Mater Health Services in 2013. In addition, Dr Griffin continues appointments as Principal Investigator at Q-Pharm, as Visiting Scientist/Honorary Research Fellow at Mater Medical Research Institute and Queensland Institute of Medical Research, and also as Senior Lecturer at The University of Queensland.

His research interests include clinical trials in the field of infectious diseases particularly malaria human challenge and transmission blocking studies, as well as the detection of antibiotic resistance particularly VRE by mass spectrometry in the clinical microbiology laboratory.



Dr Chris Hogan

Medical Advisory Board, General Practitioner

Professor Tyson is a Professor of Microbial Genomics at The Queensland University of Technology and is the Director of the Centre for Microbiome Research.

Whilst at the University of California, Berkeley he was involved in publishing the first paper regarding the use of metagenomic sequencing for assessing microbial communities. Professor Tyson is also considered a world-leading expert in microbial analysis.

Professor Tyson holds a Bachelor Science (Hons) from the University of Queensland and a PhD from the University of California, Berkeley.



Prof Maria Abreu

IBD Advisory Panel Member, Gastroenterologist

Crohn's and colitis physician-scientist. Director of Crohn's & Colitis Center, Professor of Medicine, Professor of Microbiology and Immunology, University of Miami, Miller School of Medicine, Florida, US.



Prof Jean-Frederic Colombel

IBD Advisory Panel Member, Gastroenterologist



Professor Of Medicine at Icahn School of Medicine at Mount Sinai.

Former President of European Crohns & Colitis Organisation (ECCO).

Chair of the International Organisation of Inflammatory Bowel Disease (IOIBD).



Future Milestones



Capital structure

Current shareholder register

High quality share register with strong institutional holders including Perennial, Thorney and Alium. In addition, the company has high net worth investors and KOSDAQ listed strategic investor MacroGen.

Holder	No. of Shares ('000,000)	Pre-Raise Capital (%)
Founding Team	46.3	22.3%
SA Microba Holdings	30.4	14.7%
Institutional Investors	60.2	29.0%
MacroGen	17.8	8.6%
Others	52.8	25.4%
Total Issued Capital ¹	207.5	100%

1. The number does not include 17.6m options currently on offer under the Employee Share Option Plan.

Existing shares on Issue ¹	207.5m
Current Market capitalisation	A\$83 million

Partner distribution model

Partners

Customer engagement

Partners promote to clinicians, consumers or research clients via multiple channels. Retail prices vary depending on the service and geography.

Sampling kit

Partners distribute a test kit including Microba's dry-swab sampling technology. Partners manage sample logistics.

Sequencing

Distribution partner lab utilises Microba's proprietary protocols for sample processing and metagenomic sequencing of samples.

Report delivery

Report delivered to customer by partner customer portal or report delivery system.



Dry-swab sampling technology



Microba lab protocols developed over 20 years founder experience



Microba Cloud

Data transfer, processing, storage and retrieval via scalable cloud infrastructure.



Microba

Global scalability through partner distribution model.

Data analysis

Raw metagenomic data is processed using **Microba's proprietary Analysis Platform technology.**

Report generation

Results are transformed into an easy-to-understand, user-friendly customer report and delivered back to the partner.

Phylum	Family	Genus	Species	Abundance	Prevalence	Log
Bacteroidetes	Bacteroidia	Bacteroides	Bacteroides	24.5%	0.00-1.0%	High
Firmicutes	Actinomycetia	Actinomyces	Actinomyces	1.5%	0.00-0.1%	High
Firmicutes	Firmicutes	Firmicutes	Firmicutes	0.5%	0.00-0.1%	High
Actinobacteria	Actinobacteria	Actinobacteria	Actinobacteria	4.5%	0.00-0.05%	High
Proteobacteria	Proteobacteria	Proteobacteria	Proteobacteria	4.0%	0.00-1.0%	High

Simplified Financial Model

Active Referring Practitioners (ARP)



Average Kits per month (KPM)



Average Price per Kit (AP)



Monthly Revenue Opportunity (MRO)

Next generation microbiome drug discovery approach

2005 - 2015



Fecal Microbiota Transplant

Some efficacy achieved with Faecal Microbiota Transplant in multiple indications including recurrent *Clostridium difficile* infection.

2015 - 2020



Random library screening

Random screening of cultured isolate banks.

Limited to readily accessible cultured organisms representing only 29%* of gut microbial diversity.

2020 - Future



Data-driven rational discovery

AI supported rational drug discovery leveraging large proprietary human dataset.

Targeted isolation tapping into the 71%* of previously uncultured gut microbes.

*Almeida *et al* Nature Biotechnology (2020) DOI: [10.1038/s41587-020-0603-3](https://doi.org/10.1038/s41587-020-0603-3)

Microbiome is a **growth sector** of the chronic disease management market



Microbiome Drug
Discovery Company
NASDAQ
\$630m USD mkt cap



Microbiome Drug
Discovery Company
NASDAQ
\$585m USD mkt cap



Microbiome Drug
Discovery Company
NASDAQ
\$701m USD mkt cap



Genomic testing & data-driven
drug discovery company
NASDAQ
\$5.2bn USD mkt cap

Our **personal health testing** solution

60%

Of the population experience gastrointestinal symptoms

89%

Of customers receive an actionable out-of-range result

9/10

Customer satisfaction score*

We pioneered the delivery of comprehensive microbiome reporting to empower consumers and practitioners to improve health

